Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 10,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $17.04, for a total value of $170,400.00. Following the completion of the transaction, the insider now directly owns 183,266 shares of the company’s stock, valued at $3,122,852.64. This represents a 5.17 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Centessa Pharmaceuticals Trading Down 1.8 %

Shares of NASDAQ CNTA opened at $16.95 on Friday. The firm’s 50 day moving average price is $16.73 and its 200-day moving average price is $13.89. Centessa Pharmaceuticals plc has a 52-week low of $6.65 and a 52-week high of $18.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company has a market cap of $2.23 billion, a PE ratio of -11.08 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, equities research analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of research reports. Jefferies Financial Group increased their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Guggenheim upped their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 target price for the company. Finally, BMO Capital Markets upped their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Buy” and an average target price of $25.83.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC raised its holdings in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares during the last quarter. Quarry LP boosted its holdings in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares during the last quarter. Sandia Investment Management LP purchased a new stake in Centessa Pharmaceuticals in the second quarter worth approximately $90,000. Finally, Fred Alger Management LLC bought a new stake in Centessa Pharmaceuticals in the 2nd quarter worth approximately $99,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.